Ultragenyx Pharmaceutical (RARE) Cash & Equivalents (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Cash & Equivalents for 14 consecutive years, with $175.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 37.8% year-over-year to $175.0 million; the TTM figure through Mar 2026 stood at $175.0 million (up 37.8% YoY), while the FY2025 annual figure was $421.0 million, up 141.95% from the prior year.
• Cash & Equivalents declined to $175.0 million in Q1 2026 per RARE's latest filing, from $421.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $480.7 million in Q2 2024 and bottomed at $72.6 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $196.0 million across 5 years, with a median of $159.9 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 81.47% — and 2024, when it jumped 371.0%.
• Ultragenyx Pharmaceutical's Cash & Equivalents stood at $132.9 million in 2022, then soared by 60.97% to $214.0 million in 2023, then slipped by 18.69% to $174.0 million in 2024, then jumped by 141.95% to $421.0 million in 2025, then sank by 58.43% to $175.0 million in 2026.
• Business Quant data shows RARE's Cash & Equivalents at $175.0 million in Q1 2026, $421.0 million in Q4 2025, and $202.5 million in Q3 2025.